- Novozymes 2Q Ebit was DKK865 million, missing the estimated DKK1.06 billion.
- The Ebit margin was 20.5%, lower than the estimated 24.1%.
- Ebitda was DKK1.20 billion, less than the estimated DKK1.42 billion.
- Revenue was DKK4.22 billion, falling short of the estimated DKK4.39 billion.
- Household care sales were DKK1.20 billion, slightly less than the estimated DKK1.22 billion.
- Food & Beverage sales were DKK951 million, lower than the estimated DKK1.03 billion.
- Bioenergy sales were DKK1.06 billion, exceeding the estimated DKK998.3 million.
- Grain & Tech processing sales were DKK546 million, not reaching the estimated DKK633.5 million.
- Agriculture & Feed sales were DKK460 million, less than the estimated DKK503.8 million.
- Organic revenue increased by 2%, less than the estimated increase of 4.75%.
- Net income was DKK614 million, lower than the estimated DKK758.4 million.
- Adjusted EPS was DKK2.18, less than the estimated DKK2.64.
- There were 7 buys, 9 holds, and 2 sells.
A look at Novozymes A/S Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 3 | |
| Smart Score | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Novozymes A/S, a biotechnology based company, has been given a Smartkarma Smart Score of 2-5 in five different categories. This indicates that the long-term outlook for the company is positive. In particular, the company has scored highly in the Growth and Momentum categories, which suggests that Novozymes A/S will continue to experience success in the future. Additionally, the company has scored well in the Dividend and Resilience categories, indicating that the company’s dividends and resilience are likely to remain strong.
Novozymes A/S researches, develops, produces, and sells enzymes for industrial use. The company works within three main segments: the technical enzyme market, the food enzyme market, and the animal feed enzyme market. It has a worldwide distribution network, as well as operates sales and service centers online. With its positive Smartkarma Smart Score, Novozymes A/S looks set to remain a strong and successful company in the future.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
